The US Food and Drug Administration has approved Kombiglyze, a new Type 2 diabetes drug that combines saxagliptin and metformin XR in a single tablet, according to the drug’s sponsors, AstraZeneca Plc and Bristol-Myers Squibb Co. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
